Edinburgh Research Explorer

Regenerative medicine as a disruptive technology: implications for manufacturing and clinical adoption.

Research output: Contribution to journalArticle

Related Edinburgh Organisations

Open Access permissions



  • Download as Adobe PDF

    Rights statement: Copyright © 2019 Geoffrey Banda, Joyce Tait & James Mittra. Published by Cell and Gene Therapy Insights under Creative Commons License Deed CC BY NC ND 4.0.

    Final published version, 470 KB, PDF document

    Licence: Creative Commons: Attribution-NonCommercial-NoDerivatives (CC BY-NC-ND)

Original languageEnglish
Pages (from-to)1287-1303
JournalCell and Gene Therapy Insights
Issue number10
Early online date21 Oct 2019
Publication statusPublished - 23 Oct 2019


Although Regenerative Medicine has been described as a disruptive innovation, there has been little critical enquiry into the nature and location of the disruption; leading to disruptive innovation and other situations that fall under incremental innovation. This paper, based on 10 cases in the UK, analyses the nature of disruption for allogeneic and autologous therapies in terms of manufacturing, distribution and adoption in clinical settings. We discuss the challenges of dealing with inherent variability in living systems and how this necessitate co-evolution of technologies and innovations. We propose that understanding of the distinction between disruptive and incremental innovation, and of the nature, extent and location of the disruption across sectoral value chains, can help to guide company innovation strategies and government innovation support policies for RM, as already proposed for industrial biotechnology

Download statistics

No data available

ID: 114411632